Photo: Max Gelman for Endpoints News
December 12, 2023 01:14 PM EST
R&D

Bis­pecifics con­tin­ue im­pres­sive ef­fi­ca­cy streak, but com­pa­nies look to re­duce side ef­fects: #ASH23

Lei Lei Wu

News Reporter

SAN DIEGO — Bis­pe­cif­ic an­ti­bod­ies from Re­gen­eron, John­son & John­son, Ab­b­Vie and Roche con­tin­ue to show im­pres­sive ef­fi­ca­cy in lym­phomas and myelo­ma based on new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times